Approximately 70% of patients with metastatic prostate cancer exhibit bone metastases, which constitute the primary factor contributing to the unfavorable prognosis observed in these individuals 18-20 Furthermore, MYBL2 is intricately associated with the advancement of neuroendocrine prostate cancer (NEPC) 21, metastatic hormone-sensitive prostate cancer (mHSPC) 22, and the development of castration resistance 23. The gene discussed is MYBL2; the disease is metastatic prostate carcinoma.